Penumbra, Inc. Stock Hits 52-Week Low at USD 221.26

Penumbra, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 221.26 on November 3, 2025. This marks a significant decline from its 52-week high of USD 310, reflecting the stock's recent volatility in the market.
Despite this downturn, Penumbra has shown a solid one-year performance of 20.28%, slightly outperforming the S&P 500, which recorded a gain of 19.89% over the same period. The company's market capitalization stands at USD 11,138 million, indicating its position as a notable entity within its industry.

Financial metrics reveal a price-to-earnings (P/E) ratio of 84.00, suggesting that the stock is valued at a premium compared to earnings. Additionally, Penumbra maintains a return on equity of 11.41%, highlighting its efficiency in generating profits from shareholders' equity. However, the company does not offer a dividend, and its debt-to-equity ratio is reported at -0.32, indicating a unique financial structure.

As Penumbra navigates these market conditions, its performance metrics will be closely monitored by stakeholders in the pharmaceuticals and biotechnology landscape.